Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Cabozantinib Plus High-Dose Ifosfamide for the Treatment of Relapsed or Refractory Ewing Sarcoma and Osteosarcoma, CaIRS Trial

Trial Status: active

This phase I trial studies the side effects and best dose of cabozantinib when given together with high-dose ifosfamide and to see how well it works in treating patients with Ewing sarcoma or osteosarcoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Chemotherapy drugs, such as ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cabozantinib is a small molecule receptor tyrosine kinase (RTK) inhibitor, that interferes with cell communication and growth, which may prevent tumor growth. Giving cabozantinib with high-dose ifosfamide may be safe, tolerable, and/or effective in treating patients with relapsed or refractory Ewing sarcoma or osteosarcoma.